Related Experiment Video
Updated: Mar 30, 2026

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure
Published on: February 8, 2022
Off-Label Use of Septal Occluder Devices for Recurrent Tricuspid Regurgitation Following TEER
Firas Jaly1, Holger Priebe-Brämer1, Boris Dickmann1
1Department of Cardiology, Marien Hospital Witten, University Witten/Herdecke, Witten, Germany.
Background:
Recurrent severe tricuspid regurgitation (TR) after transcatheter edge-to-edge repair (TEER) remains a therapeutic dilemma when redo clipping, surgery, or heterotopic caval valve implantation are not feasible.
Case Summary:
We report 4 high-risk patients with massive to torrential TR due to interclip coaptation defects who were treated with off-label percutaneous closure using septal occluder devices. Procedural strategy evolved from transfemoral to right internal jugular access to improve coaxial alignment and deployment control. Early atrial septal occluders embolized, whereas muscular ventricular septal defect occluders, with a broader waist, provided stable anchoring and durable TR reduction. Balloon test occlusion and meticulous intraprocedural imaging were essential to avoid iatrogenic tricuspid stenosis. Clinical outcomes ranged from sustained symptomatic improvement to persistent right heart failure in advanced disease. Together, these cases suggest that in anatomically selected patients, occluder implantation may represent a feasible salvage strategy for recurrent TR after TEER when established therapies are not possible.
More Related Videos
Related Concept Videos
Mitral Regurgitation III: Medical Management
Aortic Regurgitation III: Medical Management
Mitral Stenosis III: Medical Management

